Grifols Shares Rise on Potential Sale of Shanghai RAAS Stock for $1.5 Billion
By David Sachs
Shares in Grifols rose Wednesday after it said it is planning to reduce its shareholding in Shanghai RAAS Blood Products and that it expects to receive $1.5 billion from the move.
At 1010 GMT, shares in Grifols were up 8% to EUR11.96.
The Spanish pharmaceutical company said it has notified the Chinese pharmaceutical firm and that the matter is still in planning stages.
Grifols, which currently is the largest shareholder in Shanghai RAAS, said it will remain a significant shareholder in the Chinese company.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
June 14, 2023 06:29 ET (10:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom